Novartis grabs Simbrinza approval in Europe; AZ teams with Qiagen for Iressa diagnostic;

@FiercePharma: Happy Monday, FP readers. Tops this weekend: Merck whacks 600 sales reps as part of 8,500 bloodletting. Article | Follow @FiercePharma

@TracyStaton: ICYMI last week: CVS Caremark lays out case for new specialty-drug pricing approach in JAMA editorial. More | Follow @TracyStaton

@EricPFierce: J&J has 9-month supply of Doxil and getting new contractors line up. It's done with Bedford plant. Article | Follow @EricPFierce

@CarlyHFierce: As legislator rails on potential Valeant-Allergan deal, Wall Street lines up to fund it. More | Follow @CarlyHFierce

> Novartis' ($NVS) Alcon unit won approval in Europe for its glaucoma fighter Simbrinza; the drug was approved in the U.S. last year. Release

> Aspen Pharmacare said its stockpiles of HIV drugs are growing because of delays in government tenders for new three-in-one pills approved last April. Report

> AstraZeneca ($AZN) has teamed up with Qiagen ($QGEN) to develop a blood-based diagnostic test to identify the best patients for its lung cancer drug Iressa, and a similar deal with Roche ($RHHBY) for a diagnostic on its in-development treatment AZD9291. Report | Release

> West Virginia plaintiffs filed 13 more lawsuits against Pfizer ($PFE) alleging its Zoloft antidepressant caused their babies to be born with birth defects; the first trials in federal litigation over Zoloft's potential risk of birth defects are scheduled for September in Pennsylvania. Report

> Use of generic drugs in the U.K. grew to more than 75% of prescriptions last year, saving the National Health Service an additional £1.3 billion ($2.2 billion) annually, the U.K. government says. Release

> Indian drugmaker Wockhardt pared gains of as much as 18% Monday after the company said it doesn't plan to sell a stake. Report

Medical Device News

@FierceMedDev: Qiagen sees blood cancer biomarker Dx potential in University of Tokyo patents. FierceDiagnostics story | Follow @FierceMedDev

@StacyALawrence: Bard is acquisition shopping--with $1B in cash and pressure from Medtronic/Covidien merger. More | Follow @StacyALawrence

@VarunSaxena2: Surgeon: "Just banning the power morcellator is not going to change healthcare for women at all." More | Follow @VarunSaxena2

@MichaelGFierce: Most absorbent material on Earth gives poorly soluble drugs a boost. FierceDrugDelivery story | Follow @MichaelGFierce

@EmilyWFierce: Hospira reportedly in talks with Danone for $5B "spinversion" deal. More from the NYT | Follow @EmilyWFierce

> Op-ed: Government regulations too strict in healthcare business. Item

> Registry data shows high risk of blood clot among users of Abbott's bioresorbable stent. Report

> Apple poised to take a bite out of wearable device market with patent approved for iWatch. Article

Biotech News

@FierceBiotech: We're looking for 2014's Fiercest women in biotech. More | Follow @FierceBiotech

@JohnCFierce: With billionaire's backing, Wyss spinout aims to retire animals in R&D. News | Follow @JohnCFierce

@DamianFierce: "I wish the executives who are worried about management styles would spend some time in my home." . More from Bloomberg Businessweek | Follow @DamianFierce

@EmilyMFierce: Top 10 animal health companies of 2013. FIerceAnimalHealth feature by @EricPFierce and @JustinHeifetz | Follow @EmilyMFierce

> The Pfizer dilemma: Spurned by AstraZeneca, revenue falling and facing an R&D crisis. More

> AcelRx shares plunge after FDA rejects its pain drug/device system. News

> PaxVax nails down $62M to complete vaccine buyout, PhIII study. Item

> Zealand inks a $402M cardio-metabolic peptide program with Boehringer. Article

CRO News

> Icon will teach Cambridge students how to market drugs. Story

> Contractor ABL snags an immune-focused CRO. News

> Otsuka, Horizon team up on early-stage development. Item

> SRI's in-house CRO inks a $49M deal with NIH. Article

> Basilea picks Quintiles to move its antibiotic in Europe. More

Biotech IT News

> Report tips computational biology market to top $4.2B by 2020. News

> Cancer experts warn EU data law could 'halt' research. More

> Cancer researchers tap computers to support preclinical go/no-go decisions. Item

> Google gathering data to build a picture of a healthy human. Story

> Broad Institute set to swell psychiatric databases using $650M gift. Article

Animal Health News

> In Purina v. Blue Buffalo, how far will manufacturers go? Item

> Eco's poultry and swine antibiotic Aivlosin key to revenue growth. More

> USDA, Nebraska U. researchers find no danger in Merck's Zilmax. Story

> North American sales propel growth at Abaxis. Report

> Court stands with FDA on its approach to antibiotics use in farm animals. Article

And Finally... A proposal in the U.S. House of Representatives would speed up FDA approval for drugs already approved for sale in the E.U. Report

Suggested Articles

Monday, Bernstein analysts echoed what many were probably thinking about Novo Nordisk’s Rybselsus price: “Finally we can stop talking about it.”

Low interest rates and strong stock valuations are two top reasons why U.S. drugmakers are on the move for deals.

Despite a 45% premium offered to Allergan investors through the AbbVie buyout, one investor is suing to block the deal.